JP2018522876A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522876A5 JP2018522876A5 JP2017568160A JP2017568160A JP2018522876A5 JP 2018522876 A5 JP2018522876 A5 JP 2018522876A5 JP 2017568160 A JP2017568160 A JP 2017568160A JP 2017568160 A JP2017568160 A JP 2017568160A JP 2018522876 A5 JP2018522876 A5 JP 2018522876A5
- Authority
- JP
- Japan
- Prior art keywords
- aoi
- variable
- optionally
- composition
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 21
- 239000002245 particle Substances 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 12
- 150000002148 esters Chemical class 0.000 claims 11
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 8
- 239000000084 colloidal system Substances 0.000 claims 7
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 7
- 229960002504 capsaicin Drugs 0.000 claims 5
- 235000017663 capsaicin Nutrition 0.000 claims 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 5
- 235000010384 tocopherol Nutrition 0.000 claims 5
- 229960001295 tocopherol Drugs 0.000 claims 5
- 229930003799 tocopherol Natural products 0.000 claims 5
- 239000011732 tocopherol Substances 0.000 claims 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 5
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 4
- 235000010323 ascorbic acid Nutrition 0.000 claims 4
- 229960005070 ascorbic acid Drugs 0.000 claims 4
- 239000011668 ascorbic acid Substances 0.000 claims 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 4
- 229960002442 glucosamine Drugs 0.000 claims 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 4
- 229960004889 salicylic acid Drugs 0.000 claims 4
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims 3
- 229960003260 chlorhexidine Drugs 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 229920002567 Chondroitin Polymers 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims 2
- 238000001246 colloidal dispersion Methods 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- VLMWBWYAHNRUGC-UHFFFAOYSA-N tridecyl 2-hydroxybenzoate Chemical compound CCCCCCCCCCCCCOC(=O)C1=CC=CC=C1O VLMWBWYAHNRUGC-UHFFFAOYSA-N 0.000 claims 2
- -1 Optionally Chemical compound 0.000 claims 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- UEJYSALTSUZXFV-SRVKXCTJSA-N Rigin Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O UEJYSALTSUZXFV-SRVKXCTJSA-N 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 239000012867 bioactive agent Substances 0.000 claims 1
- 229960001948 caffeine Drugs 0.000 claims 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 230000037231 joint health Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 229940041616 menthol Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1511469.7A GB201511469D0 (en) | 2015-06-30 | 2015-06-30 | Compositions |
| GB1511469.7 | 2015-06-30 | ||
| GB1511478.8 | 2015-06-30 | ||
| GBGB1511478.8A GB201511478D0 (en) | 2015-06-30 | 2015-06-30 | Blended formulations |
| PCT/EP2016/065425 WO2017001625A1 (en) | 2015-06-30 | 2016-06-30 | Multiphasic compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021038221A Division JP2021091730A (ja) | 2015-06-30 | 2021-03-10 | 多相組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522876A JP2018522876A (ja) | 2018-08-16 |
| JP2018522876A5 true JP2018522876A5 (enExample) | 2019-07-18 |
| JP6851998B2 JP6851998B2 (ja) | 2021-03-31 |
Family
ID=56292753
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568160A Active JP6851998B2 (ja) | 2015-06-30 | 2016-06-30 | 多相組成物 |
| JP2021038221A Pending JP2021091730A (ja) | 2015-06-30 | 2021-03-10 | 多相組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021038221A Pending JP2021091730A (ja) | 2015-06-30 | 2021-03-10 | 多相組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US20190167588A1 (enExample) |
| EP (3) | EP3316856B1 (enExample) |
| JP (2) | JP6851998B2 (enExample) |
| CA (2) | CA3026484A1 (enExample) |
| DK (2) | DK3316856T3 (enExample) |
| EA (2) | EA038613B1 (enExample) |
| ES (2) | ES2879383T3 (enExample) |
| HR (2) | HRP20210903T1 (enExample) |
| HU (2) | HUE056161T2 (enExample) |
| LT (2) | LT3316857T (enExample) |
| MX (4) | MX382034B (enExample) |
| PL (2) | PL3316856T3 (enExample) |
| PT (2) | PT3316857T (enExample) |
| WO (2) | WO2017001625A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3316857T (lt) | 2015-06-30 | 2021-11-25 | Sequessome Technology Holdings Limited | Daugiafazės kompozicijos |
| EP3411012A4 (en) | 2016-02-04 | 2019-08-28 | Alastin Skincare, Inc. | COMPOSITIONS AND METHODS FOR INVASIVE AND NON-INVASIVE PROCEDURAL SKIN CARE |
| WO2019028275A1 (en) | 2017-08-03 | 2019-02-07 | ALASTIN Skincare, Inc. | COMPOSITIONS AND METHODS FOR IMPROVING LAXITY OF THE SKIN AND BODY CONTOUR |
| JP2020534285A (ja) | 2017-09-15 | 2020-11-26 | アンパサンド バイオファーマシューティカルズ インコーポレイテッドＡｍｐｅｒｓａｎｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 投与および処置の方法 |
| WO2020028694A1 (en) | 2018-08-02 | 2020-02-06 | ALASTIN Skincare, Inc. | Liposomal compositions and methods of use |
| JP2025099708A (ja) * | 2023-12-22 | 2025-07-03 | 小林製薬株式会社 | 外用組成物 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4372296A (en) | 1980-11-26 | 1983-02-08 | Fahim Mostafa S | Treatment of acne and skin disorders and compositions therefor |
| JPS60136511A (ja) | 1983-12-26 | 1985-07-20 | Eisai Co Ltd | 高尿酸血症治療剤 |
| WO1987001938A1 (en) | 1985-09-27 | 1987-04-09 | The Regents Of The University Of California | Liposome transdermal drug delivery system |
| JPS6295134A (ja) | 1985-10-21 | 1987-05-01 | Nippon Saafuakutanto Kogyo Kk | リポソ−ムの製造法 |
| US5015483A (en) | 1989-02-09 | 1991-05-14 | Nabisco Brands, Inc. | Liposome composition for the stabilization of oxidizable substances |
| US5498607A (en) | 1990-07-30 | 1996-03-12 | University Of Miami | Treatment for hypercholesterolemia |
| US6165500A (en) | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
| CA2067754C (en) | 1990-08-24 | 2002-06-04 | Gregor Cevc | Preparation for the application of agents in mini-droplets |
| US5498420A (en) | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
| ATE158175T1 (de) | 1992-07-08 | 1997-10-15 | Dianorm G Maierhofer Gmbh | Liposomen, verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels |
| FR2714382B1 (fr) | 1993-12-27 | 1996-02-02 | Roussel Uclaf | Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques. |
| FR2714596B1 (fr) * | 1993-12-30 | 1996-02-09 | Oreal | Composition cosmétique pour le traitement simultané des couches superficielles et profondes de la peau, son utilisation. |
| WO1996014083A1 (de) | 1994-11-04 | 1996-05-17 | Polymun Scientific Immunbiologische Forschung Gmbh | Applikation von sod in liposomen |
| DE4447287C1 (de) | 1994-12-30 | 1996-11-07 | Cevc Gregor | Präparat zum Wirkstofftransport durch Barrieren |
| US5902604A (en) | 1995-06-06 | 1999-05-11 | Board Of Regents, The University Of Texas System | Submicron liposome suspensions obtained from preliposome lyophilizates |
| FR2767691B1 (fr) | 1997-08-27 | 2000-02-18 | Oreal | Utilisation d'une dispersion a base de vehicules lipidiques comme composition anti-inflammatoire |
| IL122084A (en) | 1997-10-31 | 1999-09-22 | Lurident Ltd | Formulation for personal care with mucoadhesive properties |
| TR200001393T2 (tr) | 1997-11-19 | 2000-10-23 | Schering Aktiengesellschaft | Azelain asitli terkip. |
| US6165997A (en) | 1997-11-20 | 2000-12-26 | Statens Serum Institut | Phospholipids having antimicrobial activity with or without the presence of antimicrobials |
| CA2283574A1 (en) | 1998-01-16 | 1999-07-22 | Color Access, Inc. | Stabilized whitening compositions and method of preparing same |
| MXPA01002149A (es) | 1998-09-01 | 2003-03-27 | Idea Ag | Transporte electricamente controlado de penetrantes cargados a traves de barreras. |
| NZ332905A (en) | 1998-11-19 | 2000-12-22 | Immuno Lab Ltd | Transdermal pharmaceutical composition comprising liposomal bee venom |
| ES2226203T3 (es) | 1998-12-23 | 2005-03-16 | Idea Ag | Formulacion mejorada para aplicacion topica no invasiva. |
| ATE216875T1 (de) | 1999-01-27 | 2002-05-15 | Idea Ag | Nichtinvasive impfung durch die haut |
| GB9902527D0 (en) * | 1999-02-04 | 1999-03-24 | Phares Pharm Res Nv | Compositions |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| MXPA02000053A (es) | 1999-07-05 | 2003-07-21 | Idea Ag | Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables. |
| US6248728B1 (en) | 2000-03-10 | 2001-06-19 | Kansas State University Research Foundation | Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol |
| US6191121B1 (en) | 2000-04-06 | 2001-02-20 | Nicholas V. Perricone | Treatment of skin damage using polyenylphosphatidylcholine |
| WO2001076555A2 (en) | 2000-04-12 | 2001-10-18 | Liplasome Pharma A/S | Lipid-based drug delivery systems for topical application |
| TWI281407B (en) | 2000-09-18 | 2007-05-21 | Vasogen Ireland Ltd | Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| WO2002062316A1 (de) | 2001-02-08 | 2002-08-15 | Vectron Therapeutics Ag | Invasomen zur therapie von erkrankungen, ihre herstellung und verwendung |
| EA200301200A1 (ru) | 2001-05-31 | 2004-06-24 | Фармация Корпорейшн | Проникающая через кожу композиция селективного ингибитора циклооксигеназы-2 |
| JP2004535434A (ja) | 2001-06-25 | 2004-11-25 | デピユイ | 関節炎にかかった関節の処置のためのグリコサミノグリカン類のリポソームカプセル化 |
| CA2368656A1 (en) | 2002-01-21 | 2003-07-21 | Vasogen Ireland Limited | Receptor-ligand pairing for anti-inflammatory response |
| AU2003233396B2 (en) | 2002-03-13 | 2007-05-24 | Thomas Skold | Water-based delivery systems |
| EP1496887B1 (en) * | 2002-04-22 | 2016-08-03 | The Procter & Gamble Company | Personal care compositions comprising a zinc containing material in an aqueous surfactant composition |
| US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| CN1470234A (zh) * | 2002-07-23 | 2004-01-28 | 吴翠栓 | 皮肤用辣椒碱脂质体制剂 |
| JP2004131432A (ja) | 2002-10-11 | 2004-04-30 | Kumamoto Technology & Industry Foundation | 悪性腫瘍抑制剤 |
| US7473432B2 (en) | 2002-10-11 | 2009-01-06 | Idea Ag | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery |
| WO2004032900A1 (en) | 2002-10-11 | 2004-04-22 | Idea Ag | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| WO2004098524A2 (en) | 2003-05-02 | 2004-11-18 | Aronex Pharmaceuticals, Inc. | Lipid platinum complexes and methods of use thereof |
| EP1514539A3 (en) * | 2003-05-14 | 2005-05-04 | Signal Investment & Management Co. | Micro-encapsulated topical analgesic for pain relief and sleeve comprising it |
| MXPA06000805A (es) | 2003-07-21 | 2006-04-18 | Vasogen Ireland Ltd | Liposomas que contienen grupos de glicerol fosfato para tratar una condicion inflamatoria aguda. |
| JP2005179313A (ja) | 2003-12-24 | 2005-07-07 | Shu Uemura:Kk | 皮膚化粧料用基剤の製造方法および皮膚化粧料 |
| US7476432B2 (en) | 2004-05-28 | 2009-01-13 | Tecton Products | Phosphorescent pultrusion |
| EP1811961A2 (en) | 2004-11-12 | 2007-08-01 | Idea Ag | Extended surface aggregates in the treatment of skin conditions |
| WO2006086992A2 (en) | 2005-02-18 | 2006-08-24 | Liplasome Pharma A/S | Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands |
| US20070042008A1 (en) | 2005-08-18 | 2007-02-22 | Bodybio, Inc. | Compositions containing phosphatidylcholine and essential fatty acids |
| EP1933856A4 (en) | 2005-08-29 | 2008-11-19 | Sepsicure L L C | METHOD OF TREATING OR PREVENTING CONDITIONS INDUCED BY GRAM POSITIVE BACTERIA |
| TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
| MX286464B (es) | 2005-12-20 | 2011-05-10 | Cenestra Llc | Formulaciones de acido graso omega 3. |
| JP5009547B2 (ja) | 2006-03-31 | 2012-08-22 | 株式会社コーセー | 顔料とリポソームを含む化粧料 |
| US7544375B1 (en) | 2006-06-12 | 2009-06-09 | Swiss Skin Repair, Inc. | Composition |
| WO2008038292A2 (en) | 2006-09-28 | 2008-04-03 | Hadasit Medical Research Services & Development Limited | Use of glycerophospholipids for joint lubrication |
| US20080131497A1 (en) * | 2006-09-28 | 2008-06-05 | Perkins Walter R | Formulations of DNase and Methods of Use Thereof |
| JP4732307B2 (ja) | 2006-11-20 | 2011-07-27 | 株式会社アンズコーポレーション | ナノエマルション及びそれを配合した化粧料 |
| US20100130611A1 (en) | 2006-12-20 | 2010-05-27 | Cenestra Llc | Omega 3 fatty acid formulations |
| EP1938801A1 (en) | 2006-12-22 | 2008-07-02 | Biofrontera Bioscience GmbH | Nanoemulsion |
| US9511016B2 (en) | 2007-06-12 | 2016-12-06 | Epicentrx, Inc. | Topical composition for treating pain |
| ITVR20080006A1 (it) | 2008-01-23 | 2009-07-24 | David Ceretta | Apparato per la realizzazione di elementi d'impasto |
| ES2335636B1 (es) * | 2008-02-29 | 2011-05-11 | Lipotec, S.A. | Composicion cosmetica o dermofarmaceutica de micelas mixtas. |
| JP2009256331A (ja) | 2008-03-25 | 2009-11-05 | Nagase Chemtex Corp | 高尿酸血症、又は痛風の予防、改善、又は治療剤 |
| US20100105139A1 (en) | 2008-10-27 | 2010-04-29 | Remco Alexander Spanjaard | Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents |
| JP2012516889A (ja) | 2009-02-05 | 2012-07-26 | ターゲッティド デリバリー テクノロジーズ リミテッド | 微生物因子の増殖及び生存能力を低下させる方法 |
| WO2010140061A2 (en) | 2009-06-03 | 2010-12-09 | John Charles Mayo | Formulations for the treatment of deep tissue pain |
| DE112010003355T5 (de) | 2009-08-21 | 2012-07-12 | Targeted Delivery Technologies Ltd. | Veskuläre Formulierungen |
| EP2382994A1 (en) | 2010-04-26 | 2011-11-02 | Maurizio Victor Cattaneo | Ligand targeted nanocapsules for the delivery of RNAi and other agents |
| WO2011162802A1 (en) | 2010-06-21 | 2011-12-29 | Virun, Inc. | Compositions containing non-polar compounds |
| US20120045405A1 (en) | 2010-08-18 | 2012-02-23 | Gilman Miles E | Under eye cream |
| WO2012148891A1 (en) | 2011-04-29 | 2012-11-01 | Evonik Degussa Corporation | Peptide-lipid conjugates and uses thereof |
| GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
| GB201206486D0 (en) | 2012-04-12 | 2012-05-30 | Sequessome Technology Holdings Ltd | Vesicular formulations and uses thereof |
| GB201208384D0 (en) | 2012-05-14 | 2012-06-27 | Sequessome Technology Holdings Ltd | Vesicular formulations, uses and methods |
| GB201208409D0 (en) | 2012-05-14 | 2012-06-27 | Sequessome Technology Holdings Ltd | Vesicular formulations, kits and uses |
| CN105473162A (zh) * | 2013-07-31 | 2016-04-06 | 斯昆申技术控股有限责任公司 | 囊泡 |
| LT3316857T (lt) | 2015-06-30 | 2021-11-25 | Sequessome Technology Holdings Limited | Daugiafazės kompozicijos |
| CA3142730A1 (en) * | 2019-06-04 | 2020-12-10 | Aquavit Pharmaceuticals, Inc. | Methods and compositions for microflillng the skin with hyaluronic acid using microchannel technology |
-
2016
- 2016-06-30 LT LTEPPCT/EP2016/065425T patent/LT3316857T/lt unknown
- 2016-06-30 WO PCT/EP2016/065425 patent/WO2017001625A1/en not_active Ceased
- 2016-06-30 HU HUE16733595A patent/HUE056161T2/hu unknown
- 2016-06-30 MX MX2018000021A patent/MX382034B/es unknown
- 2016-06-30 EA EA201890119A patent/EA038613B1/ru unknown
- 2016-06-30 WO PCT/EP2016/065415 patent/WO2017001617A1/en not_active Ceased
- 2016-06-30 DK DK16733592.6T patent/DK3316856T3/da active
- 2016-06-30 HU HUE16733592A patent/HUE054749T2/hu unknown
- 2016-06-30 PL PL16733592T patent/PL3316856T3/pl unknown
- 2016-06-30 MX MX2018000024A patent/MX381075B/es unknown
- 2016-06-30 LT LTEP16733592.6T patent/LT3316856T/lt unknown
- 2016-06-30 PT PT167335959T patent/PT3316857T/pt unknown
- 2016-06-30 CA CA3026484A patent/CA3026484A1/en active Pending
- 2016-06-30 ES ES16733592T patent/ES2879383T3/es active Active
- 2016-06-30 PT PT167335926T patent/PT3316856T/pt unknown
- 2016-06-30 EP EP16733592.6A patent/EP3316856B1/en active Active
- 2016-06-30 US US15/739,570 patent/US20190167588A1/en not_active Abandoned
- 2016-06-30 US US15/739,575 patent/US10744090B2/en active Active
- 2016-06-30 CA CA3026466A patent/CA3026466A1/en active Pending
- 2016-06-30 HR HRP20210903TT patent/HRP20210903T1/hr unknown
- 2016-06-30 ES ES16733595T patent/ES2895910T3/es active Active
- 2016-06-30 EA EA201890120A patent/EA038208B1/ru unknown
- 2016-06-30 MX MX2021004766A patent/MX2021004766A/es unknown
- 2016-06-30 DK DK16733595.9T patent/DK3316857T3/da active
- 2016-06-30 PL PL16733595T patent/PL3316857T3/pl unknown
- 2016-06-30 HR HRP20211669TT patent/HRP20211669T1/hr unknown
- 2016-06-30 EP EP16733595.9A patent/EP3316857B1/en active Active
- 2016-06-30 EP EP21189470.4A patent/EP3954361A1/en not_active Withdrawn
- 2016-06-30 JP JP2017568160A patent/JP6851998B2/ja active Active
-
2017
- 2017-12-20 MX MX2021003510A patent/MX2021003510A/es unknown
-
2020
- 2020-07-08 US US16/923,810 patent/US20220370353A9/en not_active Abandoned
- 2020-07-14 US US16/929,009 patent/US11547665B2/en active Active
-
2021
- 2021-03-10 JP JP2021038221A patent/JP2021091730A/ja active Pending
-
2023
- 2023-10-19 US US18/490,255 patent/US20240099976A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522876A5 (enExample) | ||
| Patel et al. | Nanocrystal: a novel approach to overcome skin barriers for improved topical drug delivery | |
| Draelos et al. | Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| JP2016535777A5 (enExample) | ||
| Akhtar et al. | Exploring preclinical and clinical effectiveness of nanoformulations in the treatment of atopic dermatitis: Safety aspects and patent reviews | |
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| MX2018004376A (es) | Formulaciones inyectables de neuroesteroides que contienen nanoparticulas. | |
| JP2012062328A5 (enExample) | ||
| Garg et al. | Ancient and advanced approaches for the treatment of an inflammatory autoimmune disease− psoriasis | |
| EA201592279A1 (ru) | Фармацевтическая композиция, ее получение и применение | |
| Álvarez et al. | Nanoantibiotics based in mesoporous silica nanoparticles: New formulations for bacterial infection treatment | |
| JP2013542205A5 (enExample) | ||
| JP2016501205A (ja) | 酒さの治療のための組成物 | |
| HRP20211669T1 (hr) | Multifazni pripravci | |
| WO2018229093A8 (en) | NANOPARTICLES AS DELIVERY VEHICLES OF ACTIVE PRINCIPLES AND METHODS OF PRODUCING SAME | |
| Stephens et al. | Pilot study of topical copper chlorophyllin complex in subjects with facial acne and large pores | |
| EP2991681A4 (en) | TOPICAL COMPOSITION AND CARRIER FOR THE ADMINISTRATION OF PHARMACEUTICAL OR COSMETIC ACTIVE SUBSTANCES | |
| SI3099307T1 (en) | Use of cladribine for the treatment of neuromyelitis of the visual nerve | |
| WO2015048503A3 (en) | N-arylmethyl sulfonamide negative modulators of nr2a | |
| HK1221412A1 (zh) | 囊泡 | |
| Verma et al. | Metal nanoparticle based antibacterial nanocomposites for skin infections | |
| Del Rosso et al. | The integration of physiologically-targeted skin care in the management of atopic dermatitis: focus on the use of a cleanser and moisturizer system incorporating a ceramide precursor, filaggrin degradation products, and specific" skin-barrier-friendly" excipients | |
| JP2020527143A (ja) | ざ瘡の治療のための方法および組成物 | |
| Al Hawsawi et al. | Lichen spinulosus: case report and review of literatures |